Focuses on developing therapies for autoimmune diseases and inflammatory disorders.
Coeptis Therapeutics Holdings, Inc. is a dynamic biopharmaceutical company dedicated to advancing both generic and branded pharmaceutical products alongside cutting-edge cell therapy platforms tailored for cancer patients.
At the forefront of its product portfolio is CD38-GEAR-NK, a pioneering cell therapy designed to address CD38-related cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. Complementing this, the company is developing SNAP-CAR, a promising CAR T cell therapy platform. This platform is uniquely co-administered with tagged, tumor-specific antibodies, targeting a spectrum of tumor types spanning hematological malignancies to solid tumors. Additionally, Coeptis Therapeutics offers CD38-Diagnostic, an innovative in vitro screening tool that assesses the suitability of cancer patients for anti-CD38 mAb therapy.
Coeptis Therapeutics actively collaborates with Statera BioPharma to advance STAT-201, a therapeutic candidate aimed at addressing Crohn's disease. Additionally, through a strategic partnership with Vici Health Sciences, LLC, the company is co-developing and sharing ownership rights for CPT60621, a potential treatment targeting Parkinson's Disease. Founded in 2017 and headquartered in Wexford, Pennsylvania, Coeptis Therapeutics is committed to pioneering advancements in oncology treatments and therapeutic technologies, striving to improve outcomes for patients worldwide.